NCT06560138

A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors

An Open-label, Multi-center Phase I Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Atridia Pty Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-4602 in subjects with HER2-expressing or HER2-mutated locally advanced or metastatic solid tumors.

Conditions

• HER2-expressing or HER2-mutated Locally or Metastatic Solid Tumors

Interventions

Type	Name	Description
DRUG	SHR-4602	SHR-4602 will be administered through IV infusion.

Timeline

• Start date: 2025-03-01
• Primary completion: 2025-12-14
• Completion: 2026-09-12
• First posted: 2024-08-19
• Last updated: 2025-01-07

Locations

5 sites across 1 country: Australia